News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
30,466 Results
Type
Article (3888)
Company Profile (4)
Press Release (26573)
Multimedia
Podcasts (25)
Webinars (2)
Section
Business (9836)
Career Advice (85)
Deals (1325)
Drug Delivery (18)
Drug Development (5122)
Employer Resources (10)
FDA (895)
Job Trends (812)
News (16630)
Policy (1362)
Tag
Academia (99)
Accelerated approval (8)
Adcomms (1)
Allergies (8)
Alliances (2713)
ALS (1)
Alzheimer's disease (132)
Antibody-drug conjugate (ADC) (38)
Approvals (906)
Artificial intelligence (49)
Autoimmune disease (19)
Automation (5)
Bankruptcy (6)
Best Places to Work (571)
BIOSECURE Act (1)
Biosimilars (33)
Biotechnology (4)
Bladder cancer (7)
Brain cancer (5)
Breast cancer (62)
Cancer (394)
Cardiovascular disease (24)
Career advice (78)
Career pathing (2)
CAR-T (6)
CDC (2)
Cell therapy (40)
Cervical cancer (7)
Clinical research (4234)
Collaboration (177)
Company closure (1)
Compensation (6)
Complete response letters (8)
COVID-19 (228)
C-suite (101)
Cystic fibrosis (8)
Data (286)
Depression (5)
Diabetes (30)
Diagnostics (295)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (29)
Drug shortages (4)
Duchenne muscular dystrophy (28)
Earnings (2557)
Editorial (8)
Employer branding (5)
Employer resources (8)
Events (2793)
Executive appointments (83)
FDA (1034)
Funding (94)
Gene editing (3)
Generative AI (5)
Gene therapy (48)
GLP-1 (139)
Government (249)
Guidances (11)
Healthcare (616)
HIV (5)
Huntington's disease (13)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (3)
Immunology and inflammation (42)
Immuno-oncology (6)
Indications (5)
Infectious disease (242)
Inflammatory bowel disease (18)
Inflation Reduction Act (2)
Influenza (11)
Intellectual property (5)
Interviews (10)
IPO (449)
IRA (11)
Job creations (261)
Job search strategy (69)
JPM (11)
Labor market (6)
Layoffs (65)
Leadership (4)
Legal (286)
Liver cancer (14)
Longevity (2)
Lung cancer (77)
Lymphoma (52)
Machine learning (3)
Management (2)
Manufacturing (69)
MASH (25)
Medical device (190)
Medtech (193)
Mergers & acquisitions (908)
Metabolic disorders (157)
mRNA (17)
Multiple sclerosis (32)
NASH (6)
Neurodegenerative disease (39)
Neuropsychiatric disorders (12)
Neuroscience (236)
Neurotech (1)
NextGen: Class of 2026 (241)
Non-profit (177)
Now hiring (5)
Obesity (108)
Opinion (31)
Ovarian cancer (7)
Pain (3)
Pancreatic cancer (9)
Parkinson's disease (18)
Partnered (1)
Patents (14)
Patient recruitment (13)
Peanut (3)
People (4266)
Pharmacy benefit managers (4)
Phase 1 (1214)
Phase 2 (1690)
Phase 3 (1757)
Pipeline (348)
Policy (31)
Postmarket research (303)
Preclinical (379)
Press Release (1)
Prostate cancer (4)
Psychedelics (4)
Radiopharmaceuticals (12)
Rare diseases (52)
Real estate (217)
Recruiting (5)
Regulatory (1107)
Reports (7)
Research institute (117)
Resumes & cover letters (12)
Rett syndrome (1)
RNA editing (2)
RSV (5)
Schizophrenia (16)
Series A (23)
Series B (17)
Sickle cell disease (2)
Special edition (7)
Spinal muscular atrophy (60)
Sponsored (1)
Startups (220)
Stomach cancer (5)
Supply chain (8)
Tariffs (26)
The Weekly (25)
Vaccines (54)
Venture capital (15)
Weight loss (78)
Women's health (3)
Date
Today (7)
Last 7 days (25)
Last 30 days (115)
Last 365 days (1115)
2026 (434)
2025 (1147)
2024 (1499)
2023 (1509)
2022 (3088)
2021 (2746)
2020 (2389)
2019 (1744)
2018 (1421)
2017 (1444)
2016 (1329)
2015 (1635)
2014 (1182)
2013 (1029)
2012 (1158)
2011 (1243)
2010 (1175)
Location
Africa (67)
Alabama (3)
Arizona (15)
Asia (1434)
Australia (225)
California (431)
Canada (66)
China (62)
Colorado (3)
Connecticut (41)
Delaware (2)
Europe (6751)
Florida (13)
Georgia (11)
Illinois (41)
India (3)
Indiana (29)
Japan (18)
Kansas (1)
Kentucky (2)
Louisiana (1)
Maryland (15)
Massachusetts (310)
Michigan (12)
Minnesota (31)
Missouri (9)
Nevada (3)
New Hampshire (1)
New Jersey (66)
New York (137)
North Carolina (31)
Northern California (251)
Ohio (2)
Oklahoma (1)
Oregon (1)
Pennsylvania (30)
Rhode Island (2)
South America (63)
Southern California (127)
Tennessee (1)
Texas (29)
United States (1324)
Utah (14)
Vermont (1)
Virginia (7)
Washington D.C. (4)
Washington State (89)
Wisconsin (2)
30,466 Results for "roche boehringer mannheim".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Breast cancer
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset giredestrant was unsuccessful.
March 9, 2026
·
2 min read
·
Annalee Armstrong
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but is now nearing a potential resolution.
March 20, 2026
·
2 min read
·
Tristan Manalac
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.
February 26, 2026
·
1 min read
·
Tristan Manalac
Deals
Roche sticks with C4T, adding up to $1B for molecular glue partnership
Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.
April 9, 2026
·
2 min read
·
Tristan Manalac
Obesity
Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.
April 23, 2026
·
2 min read
·
Tristan Manalac
Weight loss
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.
March 6, 2026
·
3 min read
·
Tristan Manalac
Breast cancer
Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer
While overall survival remains immature, results so far show a clear trend in favor of Roche’s giredestrant.
December 11, 2025
·
2 min read
·
Tristan Manalac
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
The alliance will add to Roche’s RNAi efforts, which include the hypertension candidate zilbesiran, partnered with Alnylam under a July 2023 agreement.
February 3, 2026
·
1 min read
·
Tristan Manalac
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
1 of 3,047
Next
